



**Press release**  
April 18, 2016  
Gothenburg

*The Offer is not made, and this press release may not, directly nor indirectly, be distributed in or to, Australia, Hong Kong, Japan, Canada, New Zealand, South Africa or the U.S or in any other country where making of the Offer, distribution of this press release or acceptance of the Offer would be contrary to applicable laws or rules or would require further offering documentation or registration or any other measures in addition to what is required by Swedish law.*

## **XVIVO Perfusion announces a recommended public offer to the holders of shares and warrants of series 2015/2016 in Vivoline Medical**

See link for full press release:

<http://www.xvivoperfusion.com/corporate/press-releases/2016-2/>

April 18, 2016  
Gothenburg  
XVIVO Perfusion AB (publ)

For further information please contact:

Christoffer Rosenblad, CFO, tel: +1 720 616 2101, email: [christoffer.rosenblad@xvivoperfusion.com](mailto:christoffer.rosenblad@xvivoperfusion.com)

Magnus Nilsson, CEO, tel +46 31 788 2150, email: [magnus.nilsson@xvivoperfusion.com](mailto:magnus.nilsson@xvivoperfusion.com)

XVIVO Perfusion AB is a medical technology company which develops solutions and systems for assessing and preserving organs outside the body and for selecting usable organs and maintaining them in optimal condition pending transplantation. The company is headquartered in Gothenburg, Sweden, and has one office in the USA. The XVIVO share is listed on Nasdaq First North Premier and has the ticker symbol XVIVO. More information can be found on the website [www.xvivoperfusion.com](http://www.xvivoperfusion.com). The Certified Adviser is Redeye, [www.redeye.se](http://www.redeye.se).

---

XVIVO Perfusion AB (publ), Box 53015, SE-400 14 Göteborg. Corporate identity number 556561-0424.

Tel: +46 31 788 21 50. Fax: +46 31 788 21 69.

E-mail: [info@xvivoperfusion.com](mailto:info@xvivoperfusion.com). Website: [www.xvivoperfusion.com](http://www.xvivoperfusion.com)

The information provided in this press release and the press release under the link provided above is such that XVIVO Perfusion is obligated to disclose pursuant to the Takeover Rules. The information was submitted for publication on April 18, 2016 at 7:30 a.m.

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.